← board
EVO
distress 1/10 · well-funded / low risk$1.97+1%today-54% from 52w high
Revenue
$157M
Liquidity
$517M
Runway
56.3 yrs
Shares 1y
0%
Price & events
-45.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.0%
1D
+0.0%
1W
-24.8%
1M
-39.0%
3M
-45.4%
6M
-48.4%
1Y
-58.8%
2Y
-90.6%
5Y
-89.3%
All
Overview
- Market Cap
- $350.22M
- Enterprise Value
- $261.16M
- Volume
- 3.73K
- 52 Week Range
- $1.95 – $4.26
- Total Shares
- 177.78M
- Float Shares
- 266.83M
- Short %
- 0.02%
- % Held by Insiders
- 0.01%
- % Held by Institutions
- 2.15%
- RVOL
- 0.07x
- Beta
- 1.31
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 177,778,907 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $4 (+92% upside) · 4 analysts
- 2026-07-15HC Wainwright & Co.Buy
- 2025-08-14HC Wainwright & Co.Buy
- 2024-11-07HC Wainwright & Co.Buy
- 2024-08-15HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.